Objective: To study the efficacy and safety of Shenqi Fuzheng injection(SQFZI) combined with radiotherapy in treating non-small cell lung cancer (NSCLC). Method: Systematic literature searches were performed in PubMed

CBM

CNKI

VIP and WanFang Data from database inception to May 2014.Randomized controlled trials(RCTs) of SQFZI combined with radiotherapy (versus radiotherapy alone) in any language were included. No language limitation was applied.Two reviewers separately assessed the quality of each included study and extracted the data. Meta-analysis was carried out according to the method provided by the Cochrane Collaboration with RevMan5.2 software. Result: A total of 7 RCTs were included. The Meta-analysis showed that the combination of SQFZI and radiotherapy couldimprove the curative effect [OR=2.74

95%CI(1.85

4.05)

P<0.000 01]

improve the quality of life [OR=4.85

95%CI (2.65

8.89)

P<0.000 01]

improve clinical symptom[OR=4.23

95%CI(2.33

7.69)

P<0.000 01]

reduce myelosuppression [OR=0.28

95%CI(0.15

0.51)

P<0.000 1]

radiation pneumonitis [OR=0.34

95%CI(0.20

0.58)

P<0.000 1] and radiation esophagitis[OR=0.40

95%CI (0.27

0.61)

P<0.000 1] as compared with radiotherapy alone. Conclusion: The current results indicates that SQFZI can improve the curative effect on NSCLC patients

improve the quality of life

improve clinical symptom and reduce the adverse effect of radiotherapy. These findings require further confirmation with rigorously controlled trials.